학술논문
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer.
Document Type
Article
Author
Yang, James Chih-Hsin; Zhou, Caicun; Jänne, Pasi A.; Ramalingam, Suresh S.; Kim, Tae Min; Riely, Gregory J; Spira, Alexander I; Piotrowska, Zofia; Mekhail, Tarek; Garcia Campelo, Maria Rosario; Felip, Enriqueta; Bazhenova, Lyudmila; Jin, Shu; Kaur, Manmit; Diderichsen, Paul M.; Gupta, Neeraj; Bunn, Veronica; Lin, Jianchang; N. Churchill, Eric; Mehta, Minal
Source
Expert Review of Anticancer Therapy; Jan2023, Vol. 23 Issue 1, p95-106, 12p
Subject
Language
ISSN
14737140
Abstract
Copyright of Expert Review of Anticancer Therapy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)